Globus Medical (GMED) Projected to Post Quarterly Earnings on Thursday

Globus Medical (NYSE:GMED) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of $1.05 per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:00 PM ET.

Globus Medical Trading Down 0.5%

GMED stock opened at $88.29 on Thursday. The stock has a market cap of $11.82 billion, a P/E ratio of 28.48, a P/E/G ratio of 1.36 and a beta of 1.06. The stock’s fifty day simple moving average is $89.78 and its two-hundred day simple moving average is $73.43. Globus Medical has a 1-year low of $51.79 and a 1-year high of $101.40.

Insider Buying and Selling

In other news, Director Leslie V. Norwalk sold 2,000 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $202,200.00. Following the completion of the sale, the director owned 10,419 shares in the company, valued at approximately $1,053,360.90. This represents a 16.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Kelly Huller sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $90.00, for a total value of $675,000.00. The SEC filing for this sale provides additional information. Insiders have sold 31,636 shares of company stock worth $2,909,333 in the last ninety days. 18.51% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Globus Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its stake in Globus Medical by 45.9% during the first quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock worth $1,622,000 after buying an additional 7,086 shares in the last quarter. Integrated Wealth Concepts LLC increased its position in Globus Medical by 33.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock valued at $320,000 after purchasing an additional 1,085 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Globus Medical by 38.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock worth $2,228,000 after buying an additional 8,540 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of Globus Medical by 237.3% in the 1st quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after acquiring an additional 598 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Globus Medical by 8.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock valued at $25,439,000 after acquiring an additional 28,027 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research note on Tuesday, December 30th. Royal Bank Of Canada lifted their price target on shares of Globus Medical from $92.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Morgan Stanley increased their target price on Globus Medical from $70.00 to $100.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Wells Fargo & Company upped their price target on Globus Medical from $66.00 to $79.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Needham & Company LLC upgraded Globus Medical from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Globus Medical has an average rating of “Moderate Buy” and a consensus target price of $100.18.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.